The investment potential of the microbiome looks to be ramping up – as evidenced by a new, $40 million Series B round funneled into Cambridge biotech Synlogic. The company’s engineering “designer probiotics” to treat a range of diseases.
The company will focus on bringing to programs – that treat Urea cycle disease and phenylketonuria – to the clinic early next year. It also plans to use the funding to expand its “synthetic biotics” pipeline across multiple therapeutic areas.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
These altered microbes are meant to correct metabolic dysregulation in the body, righting the course of disease. It’s working with AbbVie to develop these enhanced probiotics to treat irritable bowel disease.
In 2013, Synlogic closed out a $30 million Series A round. Investors in this round include OrbiMed, Deerfield Management, Atlas Venture and New Enterprise Associates.
